ImmunityBio, Inc. is a clinical-stage biotechnology company dedicated to developing targeted immunotherapies for cancer and infectious diseases. The company leverages a proprietary platform of natural killer (NK) cell and T-cell therapies, oncolytic adenovirus technology and an Artificial Intelligence RNA (AiR) mRNA platform to stimulate and enhance the body’s immune response. ImmunityBio’s research focuses on multiplexed approaches designed to overcome tumor microenvironment resistance and drive more durable clinical responses.
The company’s pipeline includes several lead product candidates across solid tumors and viral diseases. Its NK-cell therapy programs are engineered to persist and expand in vivo, offering potential treatment options for indications such as head and neck cancer, non-small cell lung cancer and melanoma. Complementing cell therapies, ImmunityBio’s oncolytic adenovirus platform delivers immune-activating cytokines directly to tumor sites, while its AiR mRNA vaccine technology is being applied to both emerging infectious diseases and oncology settings.
Founded in 2014 under the name NantKwest and rebranded as ImmunityBio in 2021, the company is headquartered in Culver City, California. ImmunityBio was established by entrepreneur and physician Patrick Soon-Shiong, who serves as Executive Chairman. Under his leadership, the company has built collaborations with academic institutions and government agencies, including the U.S. National Institutes of Health, to advance clinical trials and co-develop next-generation immunotherapies.
ImmunityBio conducts its research and clinical programs primarily in the United States but has extended its footprint through international studies in South Africa and Asia. With a multidisciplinary leadership team of immunologists, oncology researchers and biomanufacturing experts, the company aims to translate scientific innovation into scalable treatments that address unmet medical needs across diverse patient populations.
AI Generated. May Contain Errors.
